Statistics of Chronic Myeloid Leukemia

About 15% of all leukaemia is CML. Most of these are adults, with an average age of diagnosis at 64 years. Around 50% of cases are found in people aged 64 or above. CML is rare in children.

 The 5-year survival rate reveals what percent of people live at least five years after the cancer is found. The 5-year survival rate of people having CML depends on the phase of the disease, the disease’s response to treatment and other biologic characteristics of the CML.

CML treatment research has been rapid, with several drug approvals in the last two decades. It is noteworthy that many of the new drugs for CML work well, and survival rates are continually being measured depending on these newer drugs. Due mainly to recent scientific advances in targeted treatments like imatinib (Gleevec), approved in 2001, the 5-year survival rate for CML has more than tripled from 22% for people diagnosed in the mid-1970s to 72%. One study of patients consistently taking the drug imatinib found that 90% lived at least five years.

It is noteworthy that statistics on the survival rates for people with CLL are estimated.